Camlin Fine Sciences (532834) Aandelenoverzicht
Camlin Fine Sciences Limited houdt zich samen met haar dochterondernemingen bezig met onderzoek, ontwikkeling, productie en marketing van speciale chemicaliën, ingrediënten en additievenmengsels in India en daarbuiten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
532834 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Camlin Fine Sciences Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹124.75 |
| 52 Week Hoogtepunt | ₹298.00 |
| 52 Week Laag | ₹96.30 |
| Bèta | 0.64 |
| 1 maand verandering | -9.76% |
| 3 maanden verandering | 17.27% |
| 1 Jaar Verandering | -57.21% |
| 3 jaar verandering | -20.49% |
| 5 jaar verandering | -37.28% |
| Verandering sinds IPO | 1,367.65% |
Recent nieuws en updates
Narratiefupdate • Jul 07
532834: Future Profit Margins And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target for Camlin Fine Sciences from ₹190.00 to ₹165.00, reflecting updated assumptions that combine a lower revenue growth outlook with higher expected profit margins and a reduced future P/E multiple. What's in the News for Camlin Fine Sciences Camlin Fine Sciences plans to re-designate current CFO Mr. Santosh Parab as President, Strategy and Global CFO, effective August 18, 2026, following approval at the AGM scheduled for August 11, 2026.
Narratiefupdate • Jun 23
532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.Narratiefupdate • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.Narratiefupdate • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Recent updates
Narratiefupdate • Jul 07
532834: Future Profit Margins And New Global CFO Role Will Drive Upside
Analysts have trimmed their price target for Camlin Fine Sciences from ₹190.00 to ₹165.00, reflecting updated assumptions that combine a lower revenue growth outlook with higher expected profit margins and a reduced future P/E multiple. What's in the News for Camlin Fine Sciences Camlin Fine Sciences plans to re-designate current CFO Mr. Santosh Parab as President, Strategy and Global CFO, effective August 18, 2026, following approval at the AGM scheduled for August 11, 2026.Narratiefupdate • Jun 23
532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹177.5, with only marginal tweaks to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions guiding the unchanged price target. What's in the News Camlin Fine Sciences has scheduled a Board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to approve the 33rd AGM to be held on August 11, 2026, along with other business matters, according to a Board meeting notice.Narratiefupdate • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.Narratiefupdate • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Narratiefupdate • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).Narratiefupdate • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narratiefupdate • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narratiefupdate • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narratiefupdate • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narratiefupdate • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narratiefupdate • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).Narratiefupdate • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.Narratiefupdate • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.Narratiefupdate • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).Narratiefupdate • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.Narratiefupdate • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Nieuw narratief • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Rendement voor aandeelhouders
| 532834 | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | -3.4% | 2.1% | 1.9% |
| 1Y | -57.2% | -4.9% | -1.3% |
Rendement versus industrie: 532834 presteerde slechter dan de Indian Chemicals -sector, die het afgelopen jaar een rendement van -4.9 % opleverde.
Rendement versus markt: 532834 presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van -1.3 % opleverde.
Prijsvolatiliteit
| 532834 volatility | |
|---|---|
| 532834 Average Weekly Movement | 8.5% |
| Chemicals Industry Average Movement | 6.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stabiele aandelenkoers: De aandelenkoers van 532834 is de afgelopen 3 maanden volatiel geweest in vergelijking met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van 532834 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Indian.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1931 | 661 | Ashish Dandekar | www.camlinfs.com |
Camlin Fine Sciences Limited houdt zich, samen met haar dochterondernemingen, bezig met onderzoek, ontwikkeling, productie en marketing van speciale chemicaliën, ingrediënten en additievenmengsels in India en daarbuiten. Het bedrijf biedt houdbaarheidsoplossingen, waaronder antioxidanten zoals Butylated Hydroxy Toluene en Ascorbyl palmitate; en emulgatoren, schimmelremmers, antibacteriële middelen, toxinebinders, pelletbinders, desinfecteermiddelen, energizers, conserveermiddelen, verdikkingsmiddelen en groeibevorderaars, evenals plantaardige antioxidanten, zoals gemengde tocoferolen, groene thee-extract en rozemarijnextract die worden gebruikt om de houdbaarheid te verbeteren onder de merknamen Xtendra en NaSure. Het bedrijf levert ook aroma-ingrediënten, waaronder vanilline en ethylvanilline; gezondheids- en welzijnsproducten; en prestatiechemicaliën, zoals hydrochinon en catechol.
Camlin Fine Sciences Limited Samenvatting
| 532834 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹23.96b |
| Inkomsten(TTM) | -₹274.47m |
| Inkomsten(TTM) | ₹17.23b |
1.4x
P/S-verhouding-87.3x
Koers/WinstverhoudingIs 532834 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 532834 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹17.23b |
| Kosten van inkomsten | ₹9.22b |
| Brutowinst | ₹8.01b |
| Overige uitgaven | ₹8.28b |
| Inkomsten | -₹274.47m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.43 |
| Brutomarge | 46.47% |
| Nettowinstmarge | -1.59% |
| Schuld/Eigen Vermogen Verhouding | 66.8% |
Hoe presteerde 532834 op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/16 00:45 |
| Aandelenkoers aan het einde van de dag | 2026/07/16 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Camlin Fine Sciences Limited wordt gevolgd door 9 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |